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It is widely accepted that the rate of cancer progression
varies between individuals and that this variation ex-
ceeds random expectation. This variation is apparent to
the clinician who observes patients with similar disease
relapse at different intervals after primary treatment. In
biological terms, tumors of the same histological type
are observed to grow at different rates in different pa-
tients. To a large extent, tumor recurrence can be pre-
dicted, but much of the variance remains unexplained.
Of the factors that help explain variation in prognosis,
interest to date has focused on the tumor itself (its size
and grade), the proportion of cells observed to be un-
dergoing cell division, and the presence or absence of a
host of tumor markers. Several classes of prognostic
markers have a genetic basis and are the result of somatic
mutation, including gene amplification, chromosome re-
arrangement, point mutation, and allelic loss (loss of
heterozygosity [LOH]).
Rates of recurrence can also be predicted by the type
and intensity of treatment, including the extent of sur-
gery performed, the presence of positive tumor margins
after surgery, and the use of radiotherapy and chemo-
therapy. In addition, lifestyle factors such as obesity, diet,
smoking, and inadequate social support may also influ-
ence recurrence rates and, ultimately, survival, in pa-
tients with established cancer.
A fourth class of prognostic factors is related to host
variation—that is, allelic variation of genes that may
influence the course of cancer. There has been much
progress in the past decade in the identification of genes
that, when mutated, predispose to cancer and lead to
familial clustering. Much less is known about individual
variation in genes that influence the prognosis of cancer,
once established. It is reasonable to speculate that in-
herited factors may complement those factors listed
above and may help predict long-term survival.
Cancer progression is influenced both by cell growth
rates (a function of cell division and apoptosis) and by
Received May 6, 1998; accepted for publication May 12, 1998;
electronically published June 5, 1998.
Address for correspondence and reprints: Dr. Steven Narod, Centre
for Research onWomen’s Health, 790 Bay Street, Room 750, Toronto,
Ontario M5G 1N8, Canada. E-mail: narod@ftn.net
 1998 by The American Society of Human Genetics. All rights reserved.
0002-9297/98/6301-0002$02.00
the ability of the tumor to evolve through a complex
metastatic pathway. There are several classes of candi-
date genes for host susceptibility to tumor progression.
These include genes that influence cancer susceptibility,
genes that are mutated somatically in tumors, and genes
that influence critical steps in metastasis.
Cancer Susceptibility and Outcome
It is natural to begin by asking whether the genes that
predispose to cancer may also influence the rate of pro-
gression of cancer, once established. Several clinical stud-
ies have addressed the question of whether the natural
history of cancer differs when it occurs in a carrier of a
predisposing cancer mutation. For example, several
studies compare the natural histories of hereditary and
nonhereditary breast and ovarian cancer. Rubin et al.
(1996) reported a very favorable prognosis for women
with advanced-stage ovarian cancer who carry aBRCA1
mutation. They estimated the 10-year survival rate to
be 42% for stage III and stage IV ovarian cancers—a
much better rate than expected. This information is im-
portant for clinical decisions regarding surgical preven-
tion and early detection. For example, if it were known
that ovarian tumors that develop in a woman with a
BRCA1 mutation were likely to be of high grade and
to behave aggressively, then preventive oophorectomy
would be a more rational choice than periodic ultra-
sound screening. Unfortunately, later studies of patients
with hereditary ovarian cancer were unable to confirm
the findings of improved prognosis (Brunet et al. 1997;
Johannsson et al. 1998).
Much of the discrepancy in the estimated recurrence
rates among studies of hereditary breast and ovarian
cancer appears to arise from methodological differences.
It is very difficult to obtain unbiased relative risks of
survival for hereditary versus nonhereditary cancers by
examining clinic records. Individuals at elevated risk of
cancer are often under close surveillance, and their tu-
mors may be detected at an earlier stage. Lead-time bias
may result in a spuriously elevated survival rate. Other
problems arise because of the difficulty that genetic ep-
idemiologists face in obtaining vital status and mutation
status independently in an unselected group of patients.
This is because cancer patients who are referred to a
2 Am. J. Hum. Genet. 63:1–5, 1998
genetic-counseling program are more likely to undergo
genetic testing and to have their mutation status known
than are patients who are not referred or who have died.
Even when tumor specimens are available for deceased
patients, it is technically demanding to perform geno-
typing for large genes such as BRCA1 and BRCA2. It
is comparatively easier to test the proband (who is alive),
but including the proband in the study will result in
enhanced survival estimates. Even when the proband is
excluded from the study, the problem of ascertainment
bias is not entirely eliminated, because not all families
with hereditary cancer in a population will be ascer-
tained with equal probability. Once a family is ascer-
tained, all affected relatives are usually invited to par-
ticipate. For example, if each living woman with
hereditary breast cancer in a population were equally
likely to be referred for genetic assessment, then a family
with many living affected women would be more likely
to be referred than would a family with only a single
living affected member. BRCA1 analyses are not done
in the absence of a living index patient. It is insufficient
to exclude the proband to correct for bias of this type.
Nevertheless, increasing numbers of reports are pub-
lished about survival in hereditary cancer syndromes.
Because of the difficulties inherent in using clinic pop-
ulations for estimating survival, alternate methods are
desirable. Ideally, one would like to ascertain incident
cases of cancer in a well-defined population; obtain in-
formation on mutation status, grade, stage, and other
relevant prognostic factors; and follow the patients for
an extended period of time. Unbiased survival estimates
for the hereditary and nonhereditary subgroups could
then be constructed and adjusted for stage and grade.
This method is attractive but requires x10 years of fol-
low-up.
An alternate method is to use historical cases and ar-
chived tumor specimens. For example, one might ascer-
tain mutation status on an unselected sample of breast
specimens in a hospital tumor bank and then compare
survival for women with and without mutations. This
method is ideal when there is a population with a com-
mon founding mutation and a permissive scientific en-
vironment. The study design requires the investigator to
perform anonymous genetic testing on archived material
and to link mutation results with clinical data. It is im-
portant that policy makers who wish to restrict anon-
ymous genetic testing are made aware of the critical clin-
ical information that may be lost. This approach is now
feasible for several populations, including Icelanders,
French Canadians, and Ashkenazi Jews. A small number
of recurrent BRCA1 or BRCA2 mutations have been
identified in each of these populations. Information from
these test populations might be generalized to a wider
group, but allele-specific differences may also prove
significant.
Approximately 2% of all Jewish women and ∼12%
of Jewish women with breast cancer carry mutations in
BRCA1 or BRCA2. Using archived tumor DNA, Foul-
kes et al. (1997) found the prognosis of breast cancer
in Jewish women with BRCA1 mutations to be worse
than that of Jewish women without mutations. The dif-
ference was particularly marked for women with lymph
node–negative cancer (Foulkes et al. 1998); the 5-year
survival rate for the mutation carriers with node-nega-
tive disease was 58%, compared with a 94% survival
rate for the noncarriers ( ). It will be necessary toP ! .01
confirm these observations in a larger number of patients
and in patients with other mutations. Previous studies
based on clinic patients failed to discriminate between
hereditary and nonhereditary cases (Marcus et al. 1996;
Johannson et al. 1997; Verhoog et al. 1998), possibly
because of methodological limitations.
It has long been speculated that patients with familial
colon cancer have a favorable prognosis. Hereditary
nonpolyposis colon cancer (HNPCC) is often associated
with the replication error–repair (RER) phenotype and
a germ-line mutation in one of the DNA mis-
match–repair genes. Anecdotal reports of patients who
survive a first colon cancer only to develop independent
tumors in the colon or elsewhere are supported by more
systemic research. A study from Finland found that co-
lon cancers in individuals with MLH1 mutations had a
5-year survival rate of 65%, compared with 44% for
patients with sporadic tumors (Sankila et al. 1996).Wat-
son et al. (in press) show that patients from HNPCC
families with advanced-stage colon cancer are less likely
to present with liver metastases than are patients from
a tumor registry with cancer of equivalent stage.
Several explanations have been offered to explain the
favorable course of familial colon cancer. It has been
proposed that the genetic instability that is the hallmark
of hereditary colon cancer leads to the production and
cell-surface expression of diverse abnormal proteins that
could evoke an effective immune response. In support
of this theory is the observation of a characteristic lym-
phoid infiltration of colon tumors in HNPCC, which is
known to be a favorable prognostic marker (Graham
and Appelman 1990). Others suggest that a very high
somatic mutation rate may result in derangement of crit-
ical metabolic processes, thereby enhancing cell death
(Shibata et al. 1994). The study by Watson et al. (in
press) suggests that the ability of emergent tumor emboli
to form liver metastases may be impaired. This might
be due to the reduced expression of relevant cell-surface
molecules that are required for cell adhesion and growth
in the hepatic environment. However, there is also a
reduced frequency of p53 overexpression in RER-posi-
tive colon cancers (Kim et al. 1994).
It is interesting that, despite the slow progression of
established colon cancer in HNPCC families, the rate of
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premalignant change appears to be enhanced. Most he-
reditary colon cancers (like sporadic cancers) occur in
the context of a preexisting adenomatous polyp (Jass
and Stewart 1992). Despite the very high risk of cancer
in HNPCC, the frequency of such polyps in the colons
of carriers is only modestly increased. This suggests that
high risk of colon cancer in the syndrome is the result
of a rapid transformation of a benign polyp into an
invasive cancer.
The gene mutations that underlie hereditary ovarian,
breast, and colon cancer syndromes are rare and will
account for only a small amount of the variation in
recurrence rates in a population of cancer patients. Po-
tentially of more importance are frequent polymorphic
alleles, even if the genes exert a relatively modest effect.
Genes in this class include the human leukocyte antigens
(HLA), the cytochrome P450 genes, and the gene for the
androgen receptor. Melanoma patients with stage I or
stage II disease face a greater risk of recurrence if they
carry the HLA class II allele DQB1*0301 (Lee et al.
1996). The androgen-receptor gene contains a poly-
morphic CAG-repeat sequence that ranges in length
from 8 to 31 repeat units. Short repeat lengths are as-
sociated with high transcriptional activity of the andro-
gen receptor. The length of the polymorphic tract is cor-
related with prostate cancer risk; however, the
association appears to be restricted to tumors of high
grade or advanced stage. In the Physician’s Health Study,
Giovanucci et al. (1997) found that repeat lengths of
!19 units were associated with a doubling of the risk of
cancer that had spread beyond the prostate. In contrast,
the risk of cancers confined to the gland was not meas-
urably increased. These data suggest that the androgen-
receptor polymorphisms affect the rate ofmetastatic pro-
gression from localized disease, but direct evidence of
this hypothesis is still lacking.
Heritable Variation in Genes That Are Altered as
Tumors Progress
A second class of genes that may contribute to host
susceptibility to progression is the genes found to be
somatically mutated in tumor tissue. The best known of
these include oncogenes (e.g., ERBB2, N-myc, HRAS,
and KRAS) and tumor-suppressor genes (e.g., p53, RB,
NF2, and VHL). In some tumors, these genes—when
mutated, overexpressed, or amplified—are also prog-
nostic markers. Many of the tumor-suppressor genes are
also susceptibility genes. To date, there is very little ev-
idence that allelic variants of genes in this class are re-
lated to tumor progression, but few have been studied.
Inactivating p53 mutations (or p53 overexpression) is
an adverse prognostic feature for a range of tumor types.
One might expect therefore that tumors arising in the
context of an inherited p53 mutation (the Li-Fraumeni
syndrome) would be functionally inactivated for p53
and would have a poor prognosis. To my knowledge,
these experiments have not been done. A VNTR poly-
morphism near the HRAS1 proto-oncogene has been
associated with susceptibility to a range of cancer types,
both sporadic (Krontiris et al. 1993) and inherited (Phe-
lan et al. 1996), but the locus has not been studied with
regard to cancer progression.
Possibly the best candidate genes for tumor progres-
sion are those that confer a mutator phenotype on the
individual and thereby increase the somatic mutation
rate at other loci. Cancer cell lines with microsatellite
instability (typical of HNPCC) have an increased fre-
quency of mutations in the TGF-b receptor (Markowitz
et al. 1995). The I1307K allele of the APC gene is present
in 6% of the Ashkenazi population and has recently been
associated with an increased risk of colon cancer (Laken
et al. 1997). Tumors with mutations in the I1307K allele
of the APC gene show somatic mutations at adjacent
sequences, leading to the speculation that the APC gene
polymorphism is associated with hypermutability
(Laken et al. 1997). The observation that the I1307K
allele is also associated with an increased risk of breast
cancer (M. Redston and W. D. Foulkes, unpublished
data) suggests the possibility that the somatic mutation
rate at other loci may also be increased. Defects in genes
for DNA-repair syndromes, such as xeroderma pigme-
nostum, Bloom syndrome, or ataxia-telangiectasia, are
associated with increased numbers of somatic mutations
in nonmalignant cells. It is not known whether cancer
patients, either as homozygotes or heterozygotes, with
mutations or functional polymorphisms of genes asso-
ciated with DNA repair face an increased rate of relapse.
Shen et al. (1998) have documented genetic polymor-
phisms in several genes of this class, including XRCC1,
XRCC3, and XPD and XPF, as a prelude to association
studies of cancer susceptibility and progression.
Although compelling, the hypothesis that a mutator
phenotype is an adverse prognostic feature is probably
simplistic. It may be that the rate-limiting steps in early
carcinogenesis are mutation related but that later steps
in progression depend on epigenetic phenomena. Most
cancers contain a large number of genetic mutations,
LOH events, and over- and underexpression of proteins.
Many of these changes, individually or in combination,
are also related to progression. Emerging evidence sug-
gests that the individual changes are not independent
and that, within a tumor type, there may be character-
istic gene combinations. For example, if there are 30
genes that may be mutated or otherwise abnormal in a
tumor of a particular type (e.g., breast), then there are
1109 potential subtypes, each defined by the specific
genes involved. In reality, the actual number of subtypes
is probably only a small fraction of this. Each subtype
may have a characteristic prognosis, and the overall
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range in recurrence risks may be large. If the pattern of
genetic changes associated with a hereditary cancer (i.e.,
one with an inherited mutation of one of the relevant
genes) differs systematically from that of the correspond-
ing nonhereditary cancer, then the prognosis may vary
accordingly.
Genes Controlling Metastatic Spread and Tumor
Dormancy
There are abundant candidates for host susceptibility
at the level of tumor metastasis, including genes that
control for cell adhesion, invasion, and angiogenesis and
apoptosis. The malignant cell must overcome cell-cell
adhesion to invade surrounding tissues or to formdistant
metastases. E-cadherin is an important adhesion mole-
cule in normal epithelial cells, but it is often lost in their
malignant counterparts. Perl et al. (1998) found, by us-
ing a transgenic mouse model, that the loss of E-cadherin
expression could result in the transition from a well-
differentiated pancreatic islet-cell adenoma to frank car-
cinoma. It remains to be established whether heritable
variation in the gene for E-cadherin or in othermolecules
of this class is relevant for the rate of progression from
benign to malignant tumors in humans.
The phenomenon of tumor dormancy is of particular
interest as it relates directly to relapse and prognosis.
For several tumor types, including breast andmelanoma,
the tumor growth rate is not exponential, and the rate
of clinical recurrence cannot be predicted entirely from
the rate of cell division of incipient metastases. Rather,
it appears that tumor cells may undergo a period of
dormancy followed by rapid growth and relapse. Dor-
mancy is not a state of rest, as the name implies, but
reflects a balance between cell division and apoptotic
cell death (Holmgren et al. 1995). Experimental data
suggest that angiogenesis plays a critical role in reacti-
vation, and a host of positive and negative regulators of
angiogenesis have been discovered. It will be of interest
to see whether there are functional variants of the genes
involved in the regulation of angiogenesis and, if so,
whether these also predict relapse.
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